Breaking News

Rottendorf Pharma Begins €100M Oelde Campus Project

The Oelde campus is expected to expand annual tablet production capacity to up to 10 billion tablets.

Visualization of the Rottendorf Campus. Photo: integral plan GmbH // Rottendorf Pharma.

Rottendorf Pharma has started building its Rottendorf Campus in Oelde, Germany, a major investment designed to expand manufacturing capacity for the global pharmaceutical industry.

The first phase includes a production facility and integrated logistics infrastructure. Rottendorf is investing more than €30 million ($34.8 million) in this initial phase, with total investments expected to exceed €100 million ($116 million) over the long term.

The new campus is scheduled to begin operations in 2028. Upon full build-out, the company expects to increase its annual production capacity from approximately five billion to up to ten billion tablets.

“With the new campus, we are creating the foundation to grow alongside our customers while providing additional capacity and advanced manufacturing technologies,” said Marco Niemann, Managing Director of Rottendorf Pharma. “This investment strengthens our ability to support future customer programs with greater flexibility, scalability, and long-term reliability.”

A key advantage for customers is the opportunity to engage early in the development of the new manufacturing environment. Because the facility is being built on a largely undeveloped greenfield site, production areas can be designed and configured to support future product requirements and process needs.

“New manufacturing capacity of this scale is rare in today’s CDMO market,” said Erich Scheibner, Managing Director of Rottendorf Pharma. “This creates a unique opportunity for customers to influence facility planning at an early stage and secure long-term growth capacity. Together, we can develop manufacturing environments that are optimally aligned with future products and market demands.”

The campus has been designed as a long-term growth platform with the potential for additional production areas, laboratory space, and supporting infrastructure. Sustainability is also a key component of the project. Plans include DGNB Gold certification, an electrification-focused energy concept, and on-site photovoltaic power generation.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters